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ABSTRACT

A previous study of cGMP dynamics in the ovine newborn and aduit
common carotid artery(COM) by Pearce et. ai., 1994.showed that the basai
cGMP leveis in the COM were significantiy higher in the newborn compared to

the adult(0.508±0.09 and 0.11 ±0.01 pmol cGMP • L ceii water -1,
respectively)(P<0.05), This observation may represent a significant difference
in the overall metabolism of cGMP. Furthermore, this difference may be

moduiated by maturation. Given the central importance of cGMP metabolism in
maintaining vascular tone,this difference in basal cGMP may partly explain the
high incidence of cerebrovascu|ar compticatidns in the newborn. In order to

investigate the mechanisms invoived in this phenomenon,this project was
designed with two specific aims. The first, to examine and compare the

activities of guanyiate cyciase(GC)and phosphodiesterase(PDE){the enzymes
responsible forcGMP synthesis and degradation)in newborn and aduit sheep
common carotid arteries. The second,to determine if intraceliular

compartmentalization plays a roie in PDE activity. To examine the first question,
I developed a novel technique to simultaneously estimate rates of synthesis and

degradation of cGMP in whole, unbroken arteries. The estimated synthetic rate
for cGMP in the newborn was higher compared to the aduit(7.62+ 1.14 and

5.94± 1.26 pmol cGMP • L cell water

• min

, respectively). Similarly,the

estimated rate of cGMP degradation was aiso higher in the newborn compared
to the adult(4.26±.84 and 2.88±.78 pmol cGMP • L cell water

• min

).

Aithough the synthetic and degradative rates for cGMP were different between

the two age groups,the net difference between cGMP synthesis - degradation
was similar in both the newborn and adult(3.36±.6 and 3.06±.6 pmol/ L cell

water/ min, respectively). These results indicate that the difference between

synthesis - degradation is similar in both newborn and adult, and it is the
absolute levels of cGMP which differ. In order to investigate the second

question, I compared the estimated rates of cGMP degradation for each age
group in the whole-unbroken arteries with rates determined for each age group
in broken cell preparations. I utilized a crude homogenate approach where the

rate of cGMP substrate disappearance was used as an index of PDE activity. In
the crude homogenate preparation,the rate of cGMP degradation was higher in
the adult compared to the newborn (2.406±.224 and 1.407±.157 pmol cGMP •
L cell water-t - min -1, respectively). This relationship between the newborn and
the adult is in contrast to the results of the whole-unbroken arteries. These

results suggest that intracellular compartmentalization does play a role in PDE
activity.
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INTRODUCTION

A Brief History and Overview ofcGMP Metaboiism

Cyclic nucleotides play a variety of roles in the regulation of cellular
functions in nearly all cell types. Of these roles, one of the most important, is
that of an intracellular secondary messenger within vascular smooth muscle

[Lincoln, 1989]. Two of the most abundant cyclic nucleotides are adenosine 3',
5'- cyclic monophosphate(cAMP)and guanosine 3', 5'- cyclic monophosphate
(cGMP). cAMP plays an important role in blood vessel relaxation caused by
beta-adrenergic agonists. cGMP participates in blood vessel relaxation

induced by such drugs as nitroglycerin, nitroprusside and agents that function
by stimulating the release of an endothelium derived relaxing factor(EDRF).
Although the existence of cGMP was first reported more than 25 years ago, not
long after the discovery of cAMP,the role it plays as a secondary messenger

remained mostly unexplored for 10 -12 years[Goy, 1991]. The majority of
research conducted into cyclic nucleotides was focused on cAMP. cGMP was
thought to be merely an antagonist or analogous to cAMP. Because cAMP
was considered to be an important mediator of smooth muscle relaxation, it
was then reasoned that cGMP must be a mediator of contraction. It was not

until 1977 when several investigators[Katsuki and Murad, 1977][Katsuki et al.,
1977][Schultz et al., 1977]showed that vasorelaxation induced by

nitrovasodilators (nitrogen-oxide constituents) was associated with an increase
in cGMP levels that new interest was generated in cGMP [Lincoln, 1989].

Over the last 15 years a more comprehensive picture of cGMP and its

mechanisms of vasodilatation has emerged. Figure 1 is a simpiified overview

of the biological mechanisms that participate in the cGMP cascade which leads
to relaxation in vascular smooth muscle. Under normal
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Figure 1■ A Basic OverView of cGMP Metabolism and Mechanisms of
Vasodilatation.

physiological conditions, the endothelium stimulates vascular smooth muscle
relaxation through the release of EDRF. Since its discovery in the early 1980's
{Furchgott and Zawadzki, 1980], EDRF has been shown to be essentially nitric
oxide [Hardman, 1984] [Ignarro, et al., 1987}. The endothelium can also

produce other factors which are capable of inducing reiaxation, such as
endothelium derived hyperpolarizing factor (EDHF), but these factors are not

thought to be involved in the cGMP cascade. Although the endothelium plays

the most important role in the release of nitric oxide into the smooth muscle
cells, there are other pathways for nitric oxide to enter the cell. Ignarro has

reported the presence of small quantities of NO-synthase in the smooth muscle
itself[1992 FASEB meetings, Anaheim CA]. Drugs such as nitroglycerin and

nitroprusside do not require the presence of the endothelium, and function via
biotransformation within the smooth muscle cell to release nitric oxide [Ignarro

et al., 1981][Brien et al., 1988]. Still other drugs such as S-nitroso-N-acetyl

penacillamine(SNAP) release nitric oxide spontaneously upon hydration to
serve as an exogenous source of nitric oxide [Ignarro et al., 1981].
No matter its source, nitric oxide directly stimulates guanylate cyclase

(GC)to convert the substrate guanosine triphosphate(GTP),into cGMP. Once
GO is activated,cGMP levels quickly begin to rise. cGMP then directly binds
with, and thus activates cGMP-dependent protein kinase (G-kinase). Although
the mechanics of G-kinase are not fully understood, it is known that once
activated, G-kinase acts via phosphorylation of various unknown protein
substrates within the smooth muscle cell. It has been proposed that this

phosphorylation affects at least three different pathways in order to regulate
intracellular levels of Ca2+. It is these pathways, alone or combined, that lead

to relaxation. Smooth muscle tone is dependent upon intracellular levels of
Ca2+. High levels of Ga2+ induce contraction, whereas low levels are
associated with relaxation. The first of these pathways leads to the direct

reduction of Ca2+ within the cell by the activation of Ca-ATPase pumps, which
pump Ga2+ out of the cell. The second pathway is capable of attenuating the

polyphosphoinositide cycle (specifically IPS). This reduces the amount of
stimulation by IPS on the sarcoplasmic reticulum to extrude Ca2+,thus

preventing Intracellular levels of free Ca2+ from rising [Abdel-Latif A. A., 1986].
The third pathway effects the state of force produced by the myosin and actin
filaments of the smooth muscle itself. G-kinase is capable of phosphorylation

at no less than seven sites within the myosin-actin complex,thus altering the
characteristics of the actin filaments which allow them to bind and interact with

myosin. This change in the physical characteristics of actin and myosin (which
would also Include its sensitivity to Ca2+)leads to a change in the force

produced by the vascular smooth muscle[Pearce and Harder, 1994].
Ultimately, the magnitude and the duration of relaxation is directly
linked to the amount of phosphorylation by activated G-kinase. If cGMP levels
within the cell were to remiain elevated above baseline for an extended period

of time, nearly full and complete activation of G-kinase would occur.
Conditions such as these would render the vascular smooth muscle incapable

of maintaining tone. Therefore,the cGMP signal whicti controls the activation
of G-kinase should be very short in duration. This is accomplished within the in

vivo system by a rapid and short pulse of cGMP. In order to achieve this rapid
and short pulse, not only must rapid synthesis of cGMP by GO occur, but rapid

degradation of cGMP must also occur at roughly the same time. In adult
sheep,the cGMP pulse has been shown to reach peak cGMP concentration by
60 sec. after NO stimulation, and then rapidly return back to baseline by 100

sec.[Pearce, et al., 1994]. The family of enzymes responsible for this rapid
degradation (hydrolysis of the 3'-phosphodiester bond) of cGMP,are known as

cGMP specific phosphodiesterases(PDE). The hydrolysis of cGMP in this
fashion simply yields guanosine monophosphate(GMP)which may then go on
to complete the cycle and return to GTP.

In order for an organism to possess a dynamic vascular system capable
of responding quickly and repeatedly to a changing environment, tight control
over intercellular levels of cGMP rnust be maintained. To achieve this,

synthesis and degradation of cGMP must be tightly linked together. It is the
balance or "ratio" of GO and PDE activity within the dynamic system which

determines the total magnitude of the cGMP pulse, which in turn determines
the amount of phosphorylation by G-kinase, and which finally determines the
magnitude and the duration of vasodilation.

A variety of different research projects and disciplines have lead us to
this model of cGMP induced vasodilation. Although this model supplies us

with a basic understanding, it is in no way complete. Of these projects that
have contributed to this model, one of the most interesting lines of investigation
into cGMP metabolism has been that of its regulation. Nearly all intracellular

messengers are subject to some form of regulation and cGMP is no exception.
As suggested above,two points for regulation of cGMP are its synthesis by GC,
and its degradation by PDE. The regulation of GO and PDE activity in the
cascade Of events leading to vasorelaxation is an important factor for the
overall vascular response of an organism. Considering the importance of the

cGMP synthesis/degradation relationship, a better understanding of the
enzymes responsible for each is in order.
Guanylate Cyclase

Guanylate Cyclase is the intracellular enzyme responsible for the

synthesis of cGMP from GTP. GC is found in two biochemically different forms.
One form of GC is membrane bound (particulate) and the other is cytoplasmic
(soluble). The particulate form of GC appears to be evolutionarily a very old

enzyme which can be found In most animal species and monocellular systems
[Tremblay,et al. 1988]. The membrane bound form of GC must be activated
directly by stimuli[Goy,1991]. The soluble form of GC has been found in most
mammalian ceils. It is this form of GO which is responsible for the production of

cGMP in the vascular smooth muscle. Unlike the particulate GC,soluble GC
contains an associated heme group, and must be activated indirectly via EDRF

(NO),or a number of other compounds(peroxides, unsaturated fatty acids such
as arachidonate, or certain lipids such as lysophosphatidyl choline and oleic

acid)[Goy, 1991][Pearce and Harder, 1994]. It is thought that NO activates
soluble GC by interaction with its heme component[Gerzer, et al., 1982].

Although it is conceivable that other agents capable of interacting with heme

(other free-radicals) could produce changes in GC activity, in 1987 Ignarro
proposed that NO was physiologically the most important and abundant of
these agents[Ignarro, et al., 1987]. Since that time a large body of work has
been published which supports this view.

Although both forms of GC are highly characterized, dramatic evidence

of direct regulation has never been shown for the solubie form. The existence
of some cGMP regulation via GC activity has been proposed for NO and other
free-radicals. Any alteration in these diffusible substances would increase the
response of GC. This is based on the fact that GC is sensitive to those factors
which interact with the iron-containing heme group in soluble GC. Related to
this form of regulation would be the the formation of free-radical scavengers
such as superoxide anion and/or any oxidizing compound in the tissue.
Formation of these scavengers would effectively inhibit the same GC activity
[Lincoln, 1989].

cGMP specific phosphodiesterases

Cyclic nucleotide PDEs are the intracellular enzymes responsible for the

degradation of both cAMP and cGMP. Although nearly all cGMP within the cell
undergoes hydrolysis by PDE,intracellular levels of cGMP may also be

reduced by the release of cGMP into extracellular space, this however
accounts for very little of the total cGMP removed from the cell [Schini et. al.,
1989]. At present there are over 20 known isozymes of cyclic nucleotide
specific PDEs found in various types of tissue, fibroblasts, and platelets[Beavo

and Reifsnyder 1990]. These isozymes have been divided into five distinct
families based on their biochemical characteristics (type I through V.)[Table

1]. Not only are the biochemical characteristics of these isozymes

PDE Type
1
II

Substrate

inhibitor

cAMP&cGMP

VInpoceline

Oi2f/Caimodjulin-dependent

EGTA

CAMP & cGMP
cGMP-stimulated

No specific

CAMP & cGMP

Indoilidan
Cllostamide
Quazinone

III

cGMP4nhibited

IV

cAMP-speclfic

V

cGMP

cAMP

All

cGMP-specific
nonselactive

Roiipran
Zaprkiast
(M&B22948)
IBMX

Theophyline

Table 1: Phosphodiesterase Isozyme Families and Some Selective
Inhibitors. This table is not meant to be complete. Most agents noted
show at least a 20-fold selectivity for the family listed. Information
presented in this table has been extracted from Beavo and Reifsnyder,
1990.

different, but comparison of the gene sequences for each has confirmed the

presence of multipie genes that code for the different famiiy members
[Swinnen, et al., 1989][Le Trong,et ai., 1990]. It should be noted that no
standardized nomenclature existed for the PDE types until 1990[Beavo and

Reifsnyder 1990]. Before this time each PDE isozyme was referred to by the
order in which they were eluted from a DEAE column. To complicate matters
even further, different extraction techniques yieided different PDE isozymes.

As a result much of the early literature is difficult to decipher in regards to the

PDE type being described. Despite this, a number of researchers have shown
these PDE isozymes and famiiies to be very tissue specific[Weishaar, et al.,
1986][Silver, et al., 1988][Souness, et al., 1990]. This heterogeneity in PDE
distribution, combined with the existence of drugs designed to inhibit specific

PDE types, has generated considerabie interest for clinical use [Poison, 1990].
In a traditional clinical setting, high blood pressure is treated by the use of
beta-adrenergic biockers such as propranolol and atenolol. Unfortunateiy,
vasodilatation induced in such a manner is systemic. While this has the

desired effect of lowering blood pressure, it also effects systems which require

higher blood pressures for optimum performance, such as the kidneys and
lungs. The pharmacological development of a PDE inhibitor targeted at
specific tissue would be a valuable clinical tool. This possible therapeutic
appiication has fueled a new interest in PDE activity and its regulation.
The complexity of the PDE famiiies have also produced major problems
in studying these enzymes and their regulation. Despite the difficulties
involved, a major precedent for dramatic hormonai regulation of cGMP PDEs
has been shown in the retina [Stryer, 1986 &1991]. In retinal rods and cones.
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the capture of a photon of light increases the rate of cGMP breakdown, and the
stimulus is thus transduced into decreased intracellular cGMP levels.

Additional examples of complex hormonal regulation of cyclic nucleotide PDEs
have also been shown by Dumas, et al.,(1988)and Laugier, et al.,(1988)in

the quail oviduct. The knowledge that PDEs can be, and are regulated in a
complex fashion is an indication of the important role these enzymes may play
in many cellular processes. Short-term regulation and long-term cellular

modulation by different stimuli and maturation might be one function of PDEs
[Conti, et al., 1991].

Although a great deal of research has been conducted into cGMP in
vascular smooth muscle over the last 15 years, relatively little direct work has

been done to investigate cGMP metabolism, and even less concerning the
effect of maturation on cGMP metabolism. During maturation, a vast number of

different hormones, steroids, proteins and other biochemical compounds are
produced. Such a wide range of change would encompass an even larger
sphere of affected systems. Not surprisingly, maturational changes have been
observed in the endothelium of vascular smooth muscle [Vane, et al., 1990]

[Pearce and Harder, 1994]. These changes affect the smooth muscle and its

response to reiaxation stimulation. It would therefore stand to reason, that the
cGMP metabolism in vascular smooth muscle could be directly modulated by
maturation as well. Dramatic evidence which supports this hypotheses has

been shown by Pearce, et al.,[1994]in the sheep common carotid artery [Fig.
2](data reproduced by permission of W. J. Pearce). Utilizing isolated artery

segments from newborn and adult animals, Pearce examined the effects of
maturation on the dose-response and dynamic relationships between

relaxation and cGMP synthesis. The amount of relaxation produced by a
cumulative dose response to the oGMP dependent vasodiiator SNAP, is nearly

40% greater in the newborn than the adult. This evidence suggests a
= Newborn(N=7)

□ = Adult (N=8)
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Figure 2: Cumulative Dose Response to SNAP in the Common
Carotid Artery for Both Newborns and AduitS. Arteries were
precontracted with 10 pM serotonin and 20 pM histamine. The average
relaxant responses were calculated as the precent relaxation of initial
contractile tone, and are given witn standard errors. N = 7 in the
newborn, and 8 in the adult. Data reproduced by permission of W. J.
Pearce.

larger pulse of cGMP, which in turn wouid lead to a greater amount of
phosphorylation by G-kinase, which could ultimately convey a greater

propensity for relaxation in the newborn. This marked change in relaxation
response may result in a significant physiological detriment for the newborn.
10

Newborns suffer a high incidence of cerebrovascular complications

postpartum [Rape, 1989] [DelToro, et al., 1991]. This enhanced ability for
vasorelaxation in the newborn may result in such complications as asphyxia

and transient hypertension [Rearce, et al., 1991 & 1994]. Due to problems

such as these, and the newly founded interest in the clinical use of RDE

inhibitors, a legitimate need has arisen for investigation into cGMR metabolism
alone, and as a function of age.

Project Introduction

This project has been designed with two specific aims in mind. The first,
to examine and compare GC and RDE activity in newborn and adult sheep
common carotid arteries. The second,to determine if compartmentalization
affects RDE activity.

In the first section, I have addressed a question which was raised in a

previous study by Rearce et. al.,(1994). They observed a significant difference
in the basal cGMR levels of the common carotid artery between newborn and

adult sheep. Basal cGMR levels were elevated in the newborn as compared to
the adult. This difference in the basal levels may somewhat account for the

increased efficacy of relaxation seen in Fig. 2. Furthermore, this observation
may represent a significant difference in the overall cGMR metabolism which is
modulated by maturation. Given the central importance of cGMR metabolism
and its potential for modulation by maturation, the first section of this study

addresses the hypothesis that maturation modulates cGMR metabolism by
investigating the possible mechanisms involved in this phenomenon. I have
hypothesized four likely mechanisms to explain Rearce's observation; 1) Basal

11

EDRFis greater in the newborri, corripared to the adult, 2)The SYnthetic

capacity of GC is greater in the newborn,compared to the adult, 3)PDE activity
is lower in the newborn,compared to the adult, or 4)The difference between

synthesis/degradation is Similar in both newborn and adult, and it is the
absolute levels of cGMP which differ.

Evidence which shows that compartmentalization plays a role in GG

activity has been thoroughly summarized by Waldmah and Murad [1987], but
similar information regarding PDE activity has not been forthcoming. To

address my second aim, I have conducted this study in both homogenized and
isolated intact common carotid arteries from both age groups. This

experimental design, allows me to address the recent concerns raised in the
literature that the traditional broken cell techniques used for studying PDE

activity, may actually produce physiologicaily irrelevant information [Schbeffter,
P. et a)., 1989][Ahn, H.0., et al.; 1989][Barber, R., et al., 1992]. The basic

techniques I used for the broken cell preparations(crude homogenates) are
well established [Wells, et al.1974]. Unfortunately, no experimental design has

been reported which allows for the measurement of PDE activity in intact
tissue. In order to study PDE activity in an intact preparation, I deveioped a
noveltechnique to estimate both GO and PDE activity simultaneously in a
single intact section of artery.
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METHODS

Experimental Procedures

I obtained common carotid arteries(COM)from young non-pregnant
adult sheep(age 18-24 months)and newborn lambs(age 3-5 days). Tissue

from adult animals was obtained from a local slaughterhouse within 4 hours of
slaughter, and kept packed in ice until dissection. Tissue from newborn
animals was obtained from lambs brought into the facility, and sacrificed with a

lethal injection of sodium pentobarbital on the day of the experiments.
The following is a detailed explanation for the initial treatment of the
arteries used in this study. This procedure was originally developed by Pearce
et al.,T991. three or four cm sections of arteries were cleaned of all connective

tissue and adipose tissue. Except where noted, each segment was

mechanically denuded of its endothelium using a roughened, large gauge

blunt-end hypodermic needle, and then flushed with water. By removing the
endothelium prior to the experimental procedure, I was able to eliminate any
unwanted effect of EDRF which would result in an uncontrolled stimulation of

the vascular smooth muscle. The vessel segments were cut into 3 mm ring

segments and each vascular ring was mounted on paired wires between a
force transducer (Kulite BG-10)and a post attached to a micrometer(used to

vary resting tension). During all experiments, data was continuously digitized,
normalized, and recorded using an on-line computer [Fig. 3].
In a Krebs-bicarbonate solution containing; 122mM Nad,25.6mM

NaHCOs,5.56mM dextrose,5.T7mM KCI, 2.49mM MgS04, 1.60mM CaGl2,
and 0.027mM disodium EDTA, continuously bubbled with 95% 02,5% CO2
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and maintained at 38.5-C (normal ovine core temperature), the freshly
mounted arteries were slowly and repeatedly stretched until optimum baseline

tensions of 1g [Pearce et al., 1991]remained stable for at least 30 min. In
order to replenish the vessel's intracellular stores of Ca2+,the arteries were
then contracted with an isotonic potassium Krebs solution containing 122 mM
K+ and 31 mM Na+. After peak tensions were reached, the arteries were
washed with normal sodium Krebs and allowed to re-equilibrate to baseline
tension for another 30 min.

Force Transducer
Micrometer

(iised to vary
resting tension)

38^0

Circulating
Water Pump

e
o O

95% O2 5%C02

Drainage
Figure 3: The Isolated Vessel Bath. Vessel segments were out into 3
mm ring segments and each vascular ring was mounted on paired wires
between a force transducer (Kulite BG-10) and a post attached to a
micrometer (used to vary resting tension). During all experiments, data
was continuously digitized, normalized, and recorded using an on-line
computer.
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cGMP Time Course

In order to determine if the difference in newborn and adult basal cGMP

levels observed by Pearee et at., 1994, were due to a difference in basal EDRF
levels, vessels which were both endothelium intact and endothelium denuded,

were flash frozen in liquid nitrogen at baseline condtions after a K+ contraction.

cGMP samples were taken at this point based on the previous validation work
by Pearce et a!., 1994, which has shown that basal cGMP levels remain
unchanged before or after a serotonin or K+ contraction.
To measure the normal cGMP time course, six segments from each
animal studied were used. Once a stable contraction had been achieved

using 1|iM serotonin (5-HT), each vessel was treated with 10 pM (EDmax)
aqueous S-nitroso-N-acetyj penicillamine (SNAP, an exogenous source of
nitric oxide)and flash frozen at t = Os,20s,40s,60s,80s,or 100s. In order to
estimate the GO activity alone, these experiments were also repeated with a 4
min pre-incubation in 300 pM of 3-isobutyl-1-methylxanthine (IBMX, a total

inhibitor of phosphodiesterase) dissolved in DMSO, prior to the treatment with
5-HT and SNAP. The frozen vessels were subsequently homogenized and

assayed for cGMP as described below.

Crude Homogenate Preparation
" '

I

•

In light of concerns raised in the literature that traditional broken cell
techniques for studying PDE activity may produce physiologically irrelevant
information, I performed a set of experiments to compare intact and broken cell
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determinations of PDE activity. For the broken cell technique I chose a slightly
unorthodox technique. Rather than measuring the appearance of product in

my preparation (in this case GMP), I chose to measure the disappearance of
substrate(cGMP). The reason I chose this approach, was based on two
factors. 1)The assay developed by Wells, et al.,[1975]to measure the

appearance of GMP,is extremely complicated, time consuming, and
expensive. This assay also requires equipment which I do not have at my
disposal. 2)The sensitivity of my already existing cGMP assay was extremely
high. This assay can detect down to 1.5fmol cGMP in a 75pl sample. This
range of sensitivity gave me confidence that I could accurately measure minute
changes in substrate concentration.

Approximately 20 - 30 mg (wet weight) sections of COM were

homogenized in a 40 mM Tris-HCI(pH 7.5), 1.6 mM GaGl2,2 mM MgGl2, 1 mM
dithiothreitol buffer at 4-G [Wells, et al., 1975][Weishaar, et al., 1986]. Also

added to the homogenization buffer was a mixture of protease inhibitors;
76.8 nM aprotinin, 83 mM benzamidine, 1 mM iodoacitamide, 1.1 pM
leupeptin, 7 pM pepstatin A,0.23 mM phenylmethanesulfonyl fluoride(PMSF)
[Campbell, et al., 1984]for a total of 2 ml. Samples were centrifuged at 3000g
for 30 min. An aliquot of the resulting supernate was assayed for Tris-HCI
soluble proteins as described below. The remaining supernate was divided

into six, 250pl samples and placed into tubes kept at 4-C. In order to remove

any endogenous cGMP from the preparation, each tube was individually
warmed in a 37-C wa:ter bath for a minimum 30 min "clearing period", before

the addition of substrate(10 pmol cGMP in a 0.05M sodium acetate buffer
(pH5.8)containing sodium azide[Amersham Corp., Illinois]). Early attempts at
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this protocol without the clearing period, produced varying starting levels of
cGMP. The absolute length of the clearing period did not seem to be relevant,
so long as it exceeded a minimum of 30 min. The concentration of the

substrate itself, was approximately 10x greater than reported values of Km for
PDE. With the addition of the substrate, each tube was allowed to incubate for

t = Os,5m,10m,15m,20m,or 25m. Atthe end of the incubation period 2 ml of

6% TCA was added to each tube. At this point the samples were centrifuged,
ether washed, lyophilized and assayed for remaining cGMP.

cGMP Synthesis and Degradation in Intact Segments

In order to preserve ihtracellular compartmentalization, thus more

closely emulating Xhe in vivo system of the intact artery, I have developed a
unique method for deriving both PDE and GC activity simultaneously in a

minimal amount of tissue from a single animal. I refer to this technique
thrbughout the study as the 5-30 pfotoco/.
From each animal studied,two sets of vessels, each consisting of three

adjacent vessel segments were used. To determine the synthetic capacity for

cGMP(SyN),the first set of vessels were pre-ihcubated in 300[iM IBMX for 4

min before the administration of SNAP and then flash frozen. The first segment
was frozen at t -5s,the next at t=15s,and the last at t = 30s. To determine the

net total of cGMP synthesis and degradation combined (NET),the second set

of vessels were treated only with 10 pM SNAP,and then similarly frozen. The
frozen vessels were subsequently homogenized and assayed for cGMP as

described below. The slope of the change In cGMP accumulation (pmol/mg
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protein/min) between 5s, 15s, and 30s, was used to calculate the rates of SYN
and NET. Degradation (DEG)was calculated as the algebraic difference
between SYN and NET. Because this technique calculates PDE activity as the

algebraic difference between SYN and NET, rather thari directly measuring
PDE activity, the PDE activity determined in this manner is expressed as an
estimation of activity.
One of the most important aspects of this protocol is time points at which
I chose to take my measurements at. The time points that 1 ultimately chose
were based upon the following assumption; Before peak cGMP is reached,

synthesis must be greater than degradation, as peak cGMP is reached,
synthesis must equal degradation, and finally as the cGMP level returns toward
basal values, synthesis is less than degradation. Keeping this in mind, i chose

the time points for this protocol so that both the synthetic and degradative
components were active at the same time. In addition to this consideration, I
chose not to take my first rheasurement at t = 0s, rather I took it at t = 5s; This
was in order to allow the exogenous NO released from SNAP,time to defuse
into the artery. This would ensure that all measurements would be in
enzymatically active arteries.

Cyclic Nucleotide and Protein Determinations

Frozen artery segments were stored at -80-C until assay, at which time
they were individually homogenized in 1 ml ice-cold 6% trichloroacetic acid
using a motor driven ground glass pestle and mortar(Lurex, Vineland, New

Jersey). After centrifuging the homogenates for 60 min. at SOGOg,the resulting
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pellet was used for protein determination and the decanted supernates for

subsequent cGMP assay.
Determination of protein content was identical to that previously
described by Pearce et al.,1991, except for samples from the crude

hbmogenate preparation (see below). For each protein sample,the pellet was
resuspended in 1.0 M NaOH at 37°G for 60 min. This method of extraction is
designed to exclude connective tissue and structural proteins, as previously

shown by others[Furuto et ai., 1987][Soskel et al., 1987]. After fesuspension,
the samples were centrifuged again for 60 min. at 3000 g. Aliquots of the
resulting supernates were then neutralized with an equal volume of 0.9 M HCI.
In order to avoid protein aggregation, the samples were further diluted with 125
mM urea at a 5:1 ratio of urea to sample. The protein was then quantified

using the BioRad's coomassie brilliant blue protein dye (cat#500-0006).
Bovine serum albumin served as the reference for the standard curves

determined with each set of unknowns. As has been previously shown,this
assay produces protein values which are both consistent and uniform in the
vessel type studied [Pearce et ai,, 1991].

The aliquots of Tris-HCi soluble proteins from the crude homogenate
preparation did not undergo NaOH resuspenslon or neutralization. These
samples were diluted directly with 125 mM urea at the same 5:1 ratio before

the addition of the Bradford dye.
To prepare the corresponding original supernates for cGMP

determination, each sample was washed with water saturated diethyi ether a
minimum of three times to remove the TCA used to priginaliy homogenize the
samples. Any remaining ether was allowed to evaporate, and aliquots of the
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aqueous phase were then lyophilized and stored at 4-C until assayed.

cGMP content for each sample was determined using commerciaily
available radio-immune assay(RIA) kits[RPA 525 Amersham Corp., Illinois].

The following is a brief summary of the Amersham cGMP RIA assay. The
assay is based on the competition between unlabeled cGMP and a fixed
quantity of i^spiabeied cGMP for a limited number of binding sites on a cGMP
specific antibody. With a fixed amount of antibody and radioactive ligand, the
amount of radioactive iigand bound by the antibody will be inversely

proportional to the concentration of added npn-radioactive ligand. The

antibody bound cGMP is then reacted with the Amerlex-M^"*" second antibody

reagent which contains a second antibody that is bound to rriagnetizabie
polymer particles. The antibody bound fraction is separated by centrifugation.

When the unbound radioactive supernate is decanted off from the peilet,
measurement of the radioactivity in the peiiet enabies the amount of labelled
cGMP in the bound fraction to be calculated. The concentration of unlabeled

cGMP in each sample is then determined by interpolation from a standard
curve.

Normalization

Aii reported values for cGMP were ultimately normalized to give pmol
cGMP / L ceil water. Total water content for each age group was determined

separately, as the algebraic difference between the tissue's wet weight and its
dry weight. Subsequent protein assays were performed on the dry tissue
using ether the NaOH or Tris-HCI extraction techniques to determine the ratio
of protein to total tissue water. The ratio of ceilular protein to ceil water was
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determined using the formula:

%P / %Wi> (100-%Wt)/ %Wt
where %P = %dry weight protein, %Wi= %intracellular water,and %Wt =total
%wet weight water. Both %P and %Wt were measured directly. The value

used for %Wi was taken from published values[Cox,et al. 1976]. These ratios
for both NaOH soluble protein and Tris-solubie protein were used to convert all

cGMP values into units of ixmol cGMP per liter of cell water. By normalizing to
cell water content, rather than raw protein, I was able to express cGMP as a
concentration, thus avoiding maturationai changes in protein encountered

when comparing the newborn to the adult.
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RESULTS

All reported values of n refer to the number of animals, and not the
number of segments. All values are reported as means ± SE. Unless noted,
all values for cGMP are expressed as pmol cGMP • L cell water -1. Statistical
significance was determined with a student's T test, where p <0.01 equals a
significant difference.

Basal EDRF

As Indicated In Fig. 4,the basal level In the adult COM with intact

^ 0.7
B
^ 0.6
Intact

Denuded

^0.4
CL 0.3

(g 0.2
o 0.1

0

Newborn

Adult

Figure 4: Basal cGMP In Newborns and Adults + Endothelium. All
values are given as means ± SEM. N = 12 for adults and 10 for
newborns in endothelium Intact segments. N = 15 for adults and 8 for
newborns in endothelium denuded segments.
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endothelium shows no significant difference (0.11 ±0.017)from the paired

endothelium denuded adult COM.(0.11 ±0.007). Consistent with this finding,
the corresponding newborn values for the COM with Intact endothelium (0.508
±0.098) and its paired endothelium denuded COM (0.488 ±0.064) also
showed no significant difference. For both intact and denuded,the newborn

basal cGMP levels were significantly higher than the adults.
IBMX Validation

Before I could utilize the PDE inhibitor IBMX, my first step was to

determine the concentration of IBMX needed to completely inhibit PDE activity
in my preparations. Previously reported effective doses for IBMX ranged from
1 |xM to 1 mM. In order to chose the proper dosage, Itook measurements of

cGMP in the presence of varying concentrations of IBMX(3 pM,30 pM,and

300 pM,)over a 12 min time period in endothelium intact segments. I found
that all three concentrations produced similar stable plateau values of cGMP

(data not shown). Because the concentrations tested showed a similar
capacity for cGMP inhibition, I chose the average dosage reported in the

literature, 300 pM IBMX, as my experimental concentration (Fig. 5].
Crude Homogenate Preparation.
Using the crude homogenate approach, I first examined the rates of

cGMP degradation by total PDE with, and without IBMX for both age groups.

The rate of degradation was calculated for each animal in each age group, as
the slope of the disappearance of the cGMP substrate over the first 15 minutes

of incubation. Individual animals were included or excluded from the analysis

using values of

criteria for fit. Any animal expressing an r2 value of <0.950

(95% confidence level) was excluded. Finally, the individual slopes for each
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Figure 5: Validation of the Effect of 3-lsobutyl-1-methyl-xanthine
(IBMX) in Adult Endotheiium-lntact Common Carotid Arteries. Vehicle

for IBMX is DMSO. All values are given as mean ±SEM. N =4for IBMX.
N = 7for control.
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age group were averaged and plotted using the slope to back-calculate the

mean ± SE for each time point(Om,5m, 10m,and 15m). This technique

revealed a significantly greater degradative capacity in the adult COM (2.406
+0.224 ^imol cGMP • L cell water

• min ■"') than the newborn (1.407 ±0.157

|xmol cGMP -L cell water ■■■ • min ■■') Yp <0.07J [Fig. 6]. Although
measurements qf cGMP were also taken at 20 and 25 minutes, these time
points were not included in the analysis. These time points at the extreme end

of the incubation displayed a non-linear nature. This would tend to indicate
that the concentration of the cGMP substrate had fallen below the optimum
PDE Km.

ADULT

NEWBORN
-10|i^ cGMP Substrate : ~B^Substrate+ 300|A/I IB MX

-0-1CUMcGMP Substrate "Q~SulDStrate + 30Qj.M|BM X

60

0)

I
o

40

o

0 20
stape;-1.407

O

slope: -2406 ±224
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Minutes of Incubation
Figure 6: Rates of cGMP Degradation in Crude Homogenates. All
values are given as mean +SEM, N = 5 for IBMX + cGMP, and 9 for
cGMP in the newborn. N = 5 for IBMX + cGMP, and II for cGMP in the
adult.
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cGMP Synthesis and Degradation in Intact Segments
cGMP Time Course:

When intact artery segments from each age group were treated with a

single dose of 10|xM SNAP,cGMP levels increased rapidly and peaked
between at 60s(1.41 +0;191; adult COM)and 8Gs(1.6 ±0.308; newborn

COM). After peak levels were reached,cGMP returned towards baseline

levels by 100s[Fig.7]. Although no significant differences were observed in
NEWBORN
SNAP only Hfr" SNAP +

BMX

-O-SNAP only

ADULT
HH-SN AP + 300|aM IBMX
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4-»

8

o

7
6
5-

2

O.

t

0

I

0

I

20

I

40

60

I

80

I

100

0

20

40

60

—I

80

100

Seconds of Exposure to 10^M SNAP
Figure 7: Normal SNAP-lnduced cGMP Time Course. Compared With
the Effects of IBMX on SNAP-lnduced cGMP Accumulation. All values

shown are given as mean ± SEM. The total cGMP synthesized in the
newborn wasi43.39 pmol cGMP • L cell water
and 85.54 pmol cGMP

• L cell water -I in the adult. Total synthesized cGMP was determined by
integrating the area under the normal time course curve. N = 14 in the
newborn and 10 in the adult for SNAP. N = 9 in the newborn and 8 in

the adult for SNAP/IBMX.

cGMP peak levels between age groups, a significant difference was observed

in the total cGMP synthesized in each age group. The total cGMP synthesized

in the newborn (143.39) was significantly higher than in the adult (85.54).
Total synthesized cGMP was determined as the integrated area under the time
course curve.
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When intact artery segments from each age group were pre-treated with

30P|xM IBMX before the addition of lOpM SNAP,cGMP levels increased
rapidly and reached plateau values within 100s. Once reached, this plateau

was stable for at least 12 min (as was shown in Fig 5.). Adult arteries reached
a stable plateau of approximately 2.917 +0.502 by 100s. The cGMP levels in
the newborn reached a plateau of approximately 8.416 +1.338 by 100s.
Although both age groups achieved a plateau, the level of cGMP accumulation
was significantly greater in the newborn than the adult.

PDE and GC estimation in whole artery segments:

To preserve compartmentalization, I developed a technique which
enables me to estimate the rates of cGMP degradation in whole, unbroken

arteries. This technique also enables me to make a simultaneous estimation of
the rate of cGMP synthesis from the same animal[Fig. 8]. Over the first 30s of

exposure to SNAP, both the newborn and adult have a similar net rate(NET)of

cGMP synthesis - degradation (0.056 ±0.007 and 0.051 ±0.01 pmol cGMP • L
cell water

• sec

respectively), Over the same exposure period, the

newborn displays a higher synthetic rate(SYN)than the adult (0.127 ±0.019
and 0.099 ±0.021 pmol cGMP - L cell water

• sec , respectively) When the

rates of degradation(PDE activity)for each age group are calculated as the

algebraic difference between SYN and NET,the newborns display a higher

rate of degradation when compared to the adults (-0.071 ±0.014 and -0.048
±0.013 pmol cGMP • L cell water/"' • sec ■■>, respectively). The technique used
for determining the individual slopes was identical to that used for the crude
homogenate preparation.
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Figure 8: Rates of cGMP Accumulation and Dearadation in Intact
Arteries. All values are given as mean ±SEM. N = 8 in the newborn and
13 in the adult.
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DISCUSSION

Part I: cGMP Metabolism

In the introduction, I have suggested several likely explanations for the

age-related differences in basal cGMP levels. Those explanations are; 1)

Basal EDRFis greater in the newborn, compared to the adult, 2) The synthetic

capacity of GC is greater in the newborn, compared to the adult, 3)PDE activity

is lower in the newborn, compared to the adult, or 4) The difference between
synthesis/degradation is simiiar in both newborn and adult, and it is the
absolute ieveis ofcGMP which differ. When considering the results of this
project, I believe that I can eliminate the first of these explanations. Based on

Fig.4 in which I have removed the endothelium from the ring segments and
compared the basal cGMP levels with endothelium intact ring segments, I have

clearly demonstrated that the endothelium does not effect the basal cGMP
levels.

In order to address the second and third explanations, I had to conduct

experiments which could separate each of these elements. Traditionally this
would be accomplished in a broken cell preparation, in which the enzyme in

question would be isolated, purified, and then tested in the presence of its
substrate for product appearance. Unfortunately this is not a practical

approach In the case of soluble GC. Soluble GO activity is somewhat affected
by compartmentalization [Waldman and Murad,1987]. So in order to address

the second explanation: 2) The synthetic capacityof GC is greater in the
newborn, compared to the adult, I chose a pharmacological approach in intact
tissue. By inhibiting the degradative activity of PDE with IBMX, I was able to
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measure the total accumulation of cGMP over the first 100s after exposure to

SNAP [Fig. 7]. I used this cGMP accumulation as a direct indication of GO
activity. The level of cGMP accumulation was much greater in the newborn
than the adult. This may indicate a greatly enhanced GO capacity in the
newborn relative to the adult. If this is true, this data would tend to support the

second explanation. However,a certain question casts some doubt upon this
as the sole explanation. Is this truly a measurement of CG activity, or is it an
indication that newborn and adult GTP levels are different? Substrate

exhaustion of GTP by GC could easily explain the observed differences in

plateau cGMP values. Because newborns are metabolically more active than
adults, it is conceivable that greater levels of GTP do exist in the newborn
compared to the adult. An extensive search of the literature yielded no

information on this possibility. As such,the second explanation can neither be
proven nor eliminated at this point. In light of this consideration, what can be
stated is; whether due to a difference in GC or substrate availability, the

newborn does have a higher capacity for cGMP synthesis compared to the
adult in an in vivo situation.

When I began to consider the third explanation: 3)PDE activity is iower
in the newborn, compared to the aduit, I encountered the problem of PDE
compartmentalization. The likelihood that PDE activity was affected by

compartmentalization was extremely high. Despite this likelihood, studies
involving PDE families and subtypes have all previously been conducted in a
traditional broken cell preparation. To complicate matters even further, the
published values for PDE Vmax and Km are both wide and varied. This
variation could be accounted for by the extraction and isolation techniques
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utilized by each study. Rather than simply repeating similar experiments to

investigate possible maturational changes in PDE activity, I chose to
investigate PDE activity in both intact and homogenized arteries. For the
broken cell technique I chose to use crude homogenates rather than an

isolated and purified enzyme preparation for three reasons. 1) A crude

homogenate preserves any possible enzyme co-factors that may be required
by PDE for optimum activity. 2) Enzyme purification requires large quantities of
tissue, which necessitate the pooling of tissue from several animals; This
technique makes the determination of PDE activity from a single animal

impossible. 3)In an/A7 wVo system,the total amount and velocity of cGMP
degradation, is a function of the combined actiyities of all PDE types present.

An isolated PDE preparation only yields data for a single PDE species, and
does not accurately reflect the in vivo system.

Utilizing this crude homogenate approach, I was able to examine the

rates of cGMP degradation by PDE with and without IBMX for both age groups.
This technique revealed nearly a two fold greater degradative capacity in the
adult [Fig. 6]. Based solely on this data, it would appear that the lower basal
levels found in the adult are due to the adult's greater PDE activity. Data
collected in this manner would tend to support the third explanation Although I
was able to determine the apparent rates of degradation for each age group

with this technique,these rates are only an expression of the Vmax for PDE.
Whereas I could control the starting concentrations of substrate in my

preparations, the same is not true for the starting concentrations of PDE. Vmax
values are extremely sensitive to enzyme concentrations and characteristics.
Both of these factors can change from animal to animal, and from preparation
to preparation.
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I also chose to investigate PDE activity in intact arteries. The technique
that I developed to accomplish this is the is the 5-30 protocol. The advantage
of this technique over the crude homogenate approach, is that not only does it

enable me to estimate the rates of cGMP degradation in whole, unbroken
arteries, it also enables me to make a simultaneous estimation of the rate of

cGMP synthesis from the same animal. Although the 5-30 protocol is an in
vitro approach, it more accurately duplicates the in vivo situation and
eliminates much of the animal to animal variation encountered in the

homogenate approach. If I apply the 5-30 protocol to examine the degradative

component alone, the estimated PDE activity is higher in the newborn
compared to the adult[Fig. 8]. When this data is compared with that from the
homogenate experiments, the results produced are completely opposite. In

order to decide which of the two preparations best represent the in vivo
situation, I have gone back to the results of the second question. If the results
from the second question can be accepted as accurately reflecting the in vivo
situation due of the intact nature of the experiment, I must accept the intact PDE
preparation as the preparation which most accurately reflects the in vivo

situation. In doing so,the results of the intact PDE preparation must therefore
eliminate the third explanation for the age-related differences in basal cGMP

levels. Although accepting the intact preparation has eliminated an
explanation, it has also provided a clue that supports the fourth explanation.

I believe that my final explanation: 4)The difference between synthesis/
degradation is similar in both newborn and adult, and it is the absolute levels

ofcGMP which differ, represents the best mechanism for the age-related

differences in basal cGMP. |n order to justify this explanation, I must utilize
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data from both the 5-30 protocol [Fig. 8], and the normal cGMP time course
[Fig. 7]. Now when I consider 5-30 protocol [Fig. 8], I have Included all of

the components in the technique. Both synthesis and degradation are higher
in the newborn compared to the adult, but the net total of cGMP synthesis and
degradation combined is nearly the same. This indicates that regardless of the
absolute rates of the synthesis or degradation, when fully activated, the net
effect of the enzymes are the same.

Further support for this explanation can be found in the normal cGMP

time course. During the dynamic measurements of cGMP responses to SNAP
seen in Fig. 7, the age-related differences observed under basal conditions
do not persist at peak cGMP levels. Because the peak values in the newborn

are similar to those of the adult, the difference between synthesis and
degradation during maximal activation appears unaffected by age. It remains
possible, however, that the absolute levels of both synthesis and degradation

are quite different in the newborn and adult. This is indicated by the significant
difference observed in the total mass of cGMP synthesized in each age group.

The total cGMP synthesized in the newborn was higher than in the adult.
Because the difference between synthesis/ degradation is similar in both
newborn and adult, the inital rise, time to peak, and cGMP level at peak are all
similar. Furthermore, the relationship between synthesis and degradation of
cGMP is similar in both the adult and newborn arteries, however, the total mass

of cGMP synthesized following a given stimulus is greater in the newborn than
adult arteries, and hence the impact of the same amount of degradation is

correspondingly less. This results in a net greater mass of cGMP synthesis,
greater secondary phosphorylation, greater attenuation of vascular tone and
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ultimately more prolonged relaxation state in the newborn as compared to the
adult arteries, for the same stimulus. The higher basal levels of cGMP seen in

the newborn arteries reflects the lesser impact of degradation of cGMP in the
newborn as compared to the adult vessels. This observation combined with

the findings of the 5-30 protocol lends considerable support to the fourth
explanation. A better graphic representation of this statement can be seen in
Fig. 9. which summarizes Fig.8 and helps to more clearly illustrate the
difference in the absolute levels of cGMP between the age groups.
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Figure 9: The Differences Between Synthesis and Degradation of
cGMP are Shown for Newborn and Adult Arteries. All values are given
as means N = 8 in the newborn and 13 in the adult.
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Part II: Compartmentalization

The second section of this project was designed to determine if

compartmentalization plays a role in PDE activity. I first hypothesized that

compartmentalization may play a role in smooth muscle PDE activity when I
considered the role it plays in GC activity. The subcellular distribution of GC in
smooth muscle suggests that each enzyme isoform has a unique biological
role. Whereas the soluble form might be situated to respond to intracellular
cues and to react to diffusible substances such as NO,the membrane-bound

enzyme seems poised to respond to extracellular messages. This elegant

compartmentalization of cGMP synthesis undoubtedly has some physiological
significance which is utterly destroyed in homogenized preparations [Lincoln,
1989]. Given the closely linked interrelationships between GC and PDE,the
likelihood that PDE activity is also affected by compartmentalization is
extremely high.

Further evidence for this possibility can be found in the PDE literature
itself. Not only are the published values for PDE Vmax and Km varied,
several of the PDE subtypes require co-factors that are known to be

compartmentalized or subject to constant fluxes in availability. PDE type I is
dependent upon both Ca2+ and calmodulin. PDE types II and III are either
stimulated or inhibited by cGMP availability. In addition to co-factors, in intact
tissue, PDE effectiveness is the result of one or more of the subtypes working

in conjunction with one another. It is these considerations which lead me to
believe the PDE activity was effected by compartmentalization.

Much to my surprise, none of the available data on PDE activity took into
account the possible effect of compartmentalization. What I did find were
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enzyme studies which methodically purified and isolated the different PDE
families and isozymes, determined their various Vmax's and /Cm's , and then
extrapolated those activities to physiological relevance. Although the
identification, classification and characterization of the PDE enzymes is an

important first step, accurately duplicating the necessary factors for optimum

activity in a purified and isolated preparation, is virtually impossible.
Unfortunately the only existing data regarding PDE activity is from preparations
of this type.
It is this situation which led me to develop the 5-30 profoco/. As

previously described, I conducted this study in both homogenized and isolated
intact common carotid arteries from both age groups. I then compared the

results from the two techniques, and found a dramatic difference between the
two. The homogenate technique revealed nearly a two fold greater
degradative capacity in the adult compared to the newborn. The 5-30 protocol
indicated the opposite. When I utilized the intact preparation of the 5-30

protocol, the degradative capacity of PDE was greater in the newborn as
opposed to the adult. When I compared the actual calculated rates of
degradation between the two techniques, further discrepancies were
observed. The rates of degradation for the newborn and adult in the

homogenate preparation were 1.407 and 2.406 ixmol cGMP • L cell water -i •
min -I, respectively. When the estimated rates for the 5-30 protocol are
converted to the same units as the homogenate preparation, the rates for the

newborn and adult become,4.26 and 2.88 pmol cGMP • L cell water

• min -i,

respectively. Although the rates for the adult appear similar between the two

techniques, the rates for the newborn are still very different. The rate similarity
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between the techniques in the adult, can be easily explained by the relative
differences in the cGMP substrate concentration of the two techniques. In the

intact tissue, the PDE isozymes operate in an environment which never

exceeds 2 pmol cGMP • L cell water -1. In the homogenate preparation, the
PDE isozymes are exposed to a cGMP substrate in excess of five time higher
than that in the intact tissue. As previously stated, the calculated rate of

degradation In the crude homogenate is actually an expression of Vmax. As

such, any value for the 1/ value can be altered depending upon the
concentration of substrate. As the substrate concentration drops due to

degradation, the rate changes and becomes non-linear. This phenomenon

was observed during the actual homogenate experiments. When the cGMP
substrate concentration began to approach physiological levels in the time
points at the extreme end of the incubation, rates of degradation began to
display a non-linear nature. This is a strong indication that the

compartmentalization of the intact tissue allows the PDE isozymes to function
at an optimum activity which can only be achieved in the homogenate

preparation when the substrate is well in excess of physiological levels. With

regards to the newborn, although the difference in the rates of degradation is
maintained between the two techniques, this same explanation still applies.

Although this data is not conclusive, the difference in results between
the crude homogenates and the 5-30 protocol, strongly indicates that
compartmentalization plays a physiologically important role in PDE activity.
As I developed and considered the results of the 5-30 protocol, a

practical application for my technique occurred to me. The 5-30 protocol may
prove to be extremely useful with the development of new PDE inhibitors.

37

Drugs such as zaprinast and quazinone which inhibit specific PDE isozymes,

display a vast potential for clinical usage as tissue specific vasodiolaters.
These drugs may be greatly superior to the traditional nitrovasodilators or beta
adrenergic blockers on two accounts; 1) many of the new PDE inhibitory drugs
do not show the propensity for the development of tolerance[Poison, 1990], 2)

due to the heterogeneity of PDE isozyme distribution, drugs with a selective
PDE inhibition may be used to target specific tissue [Poison, 1990]. The

selective inhibition of a single PDE isozyme within a target vascular bed, such
as the cerebral circulation, would permit the subtle manipulation of intercellular

cGMP levels and thus produce vasodilation exclusively in the target arteries.
Unfortunately the development of any drug intended for human use requires
extensive animal testing. Utilizing present techniques, large numbers of

animals would be required to provide a sufficient quantity of tissue to test. Not
only is the validity of these techniques in question, harvesting a sufficient
quantity of tissue to test the efficacy of a drug targeted on the smaller vascular
beds such as the cerebral arteries, would prove to be extremely difficult and

costly. My technique has the potential of minimizing the number of animals
normally required for testing, and readily allow for testing in specific vascular
beds.

In conclusion the difference between synthesis/ degradation is similar in
both newborn and adult, and it is the absolute levels of cGMP which differ. It is

this mechanism that best explains the age-related differences in basal cGMP.
The most important finding of this study is that the rates for PDE degradation

are significantly different between the whole-unbroken and the homogenized
preparations.
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